JOP20210282A1 - بولي ببتيد اندماج يتضمن منطقة fc لجلوبيولين مناعي وgdf15 - Google Patents

بولي ببتيد اندماج يتضمن منطقة fc لجلوبيولين مناعي وgdf15

Info

Publication number
JOP20210282A1
JOP20210282A1 JOP/2021/0282A JOP20210282A JOP20210282A1 JO P20210282 A1 JOP20210282 A1 JO P20210282A1 JO P20210282 A JOP20210282 A JO P20210282A JO P20210282 A1 JOP20210282 A1 JO P20210282A1
Authority
JO
Jordan
Prior art keywords
gdf15
immunoglobulin
region
fusion polypeptide
fusing
Prior art date
Application number
JOP/2021/0282A
Other languages
English (en)
Inventor
Ji A Park
Saem Jung
Myung Won Jin
Young Dok Son
Yeonchul Kim
Kyeongsik Min
Kyubong Na
Soomin Noh
Ji Ho Hong
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of JOP20210282A1 publication Critical patent/JOP20210282A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

غير متوفر
JOP/2021/0282A 2019-04-23 2020-04-22 بولي ببتيد اندماج يتضمن منطقة fc لجلوبيولين مناعي وgdf15 JOP20210282A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190047558 2019-04-23
PCT/KR2020/005324 WO2020218827A1 (ko) 2019-04-23 2020-04-22 면역글로불린의 Fc 영역 및 GDF15를 포함하는 융합 폴리펩타이드

Publications (1)

Publication Number Publication Date
JOP20210282A1 true JOP20210282A1 (ar) 2023-01-30

Family

ID=72941168

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0282A JOP20210282A1 (ar) 2019-04-23 2020-04-22 بولي ببتيد اندماج يتضمن منطقة fc لجلوبيولين مناعي وgdf15

Country Status (19)

Country Link
US (1) US20230053119A1 (ar)
EP (1) EP3978518A4 (ar)
JP (2) JP2022530216A (ar)
KR (2) KR20200124176A (ar)
CN (1) CN113767112A (ar)
AU (1) AU2020260931B2 (ar)
BR (1) BR112021021271A2 (ar)
CA (1) CA3136969A1 (ar)
CL (1) CL2021002757A1 (ar)
CO (1) CO2021014413A2 (ar)
IL (1) IL287343A (ar)
JO (1) JOP20210282A1 (ar)
MX (1) MX2021012964A (ar)
PE (1) PE20220500A1 (ar)
SG (1) SG11202111570TA (ar)
TW (2) TW202100563A (ar)
UA (1) UA128626C2 (ar)
WO (1) WO2020218827A1 (ar)
ZA (1) ZA202108437B (ar)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4351628A1 (en) * 2021-05-21 2024-04-17 Yuhan Corporation Composition for preventing or treating non-alcoholic fatty liver disease or non-alcoholic steatohepatitis comprising growth differentiation factor-15 variant
CN115925982A (zh) * 2021-08-24 2023-04-07 广东东阳光药业有限公司 Gdf15融合蛋白及其用途
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ282849A (en) * 1994-03-29 1998-05-27 Celltech Therapeutics Ltd Antibodies against e-selectin; whole antibodies of neutral isotype, being variants of natural antibodies altered in the fc region
US6992174B2 (en) * 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US7736653B2 (en) * 2003-11-13 2010-06-15 Hanmi Pharm. Co., Ltd Pharmaceutical composition comprising an immunoglobulin Fc region as a carrier
KR101038126B1 (ko) 2010-11-30 2011-05-31 주식회사 엘지생명과학 새로운 융합 프로모터 및 이를 포함하는 재조합 벡터
KR101868139B1 (ko) 2010-11-30 2018-06-15 주식회사 엘지화학 새로운 융합 프로모터 및 이를 포함하는 재조합 벡터
ES2942455T3 (es) * 2011-04-13 2023-06-01 Bristol Myers Squibb Co Proteínas de fusión Fc que comprenden enlazadores o disposiciones nuevos
BR112014018575A2 (pt) * 2012-01-26 2017-07-04 Amgen Inc polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)
US9550819B2 (en) * 2012-03-27 2017-01-24 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
EP2950807B1 (en) * 2013-01-30 2018-03-28 NGM Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
LT3027642T (lt) * 2013-07-31 2020-10-12 Amgen Inc. Augimo ir diferenciacijos faktoriaus 15(gdf-15) konstruktai
KR102092225B1 (ko) 2014-04-30 2020-03-23 주식회사 엘지화학 고효율 분비능을 가지는 단백질 분비 인자 및 이를 포함하는 발현 벡터
US10588980B2 (en) * 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
MD20170035A2 (ro) * 2014-10-31 2017-09-30 Ngm Biopharmaceuticals Inc Compoziţii şi metode de utilizare pentru tratamentul tulburărilor metabolice
SI3298030T1 (sl) * 2015-05-18 2023-05-31 Pieris Pharmaceuticals Gmbh Protirakav fuzijski polipeptid
KR102668200B1 (ko) * 2015-10-28 2024-05-23 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
EP3393494A1 (en) * 2015-12-22 2018-10-31 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
WO2019199685A1 (en) * 2018-04-09 2019-10-17 Amgen Inc. Growth differentiation factor 15 fusion proteins

Also Published As

Publication number Publication date
BR112021021271A2 (pt) 2021-12-21
SG11202111570TA (en) 2021-11-29
EP3978518A4 (en) 2022-11-02
CO2021014413A2 (es) 2021-11-19
IL287343A (en) 2021-12-01
CA3136969A1 (en) 2020-10-29
CL2021002757A1 (es) 2022-06-10
JP2022530216A (ja) 2022-06-28
TW202337914A (zh) 2023-10-01
WO2020218827A1 (ko) 2020-10-29
US20230053119A1 (en) 2023-02-16
KR20210080339A (ko) 2021-06-30
ZA202108437B (en) 2023-07-26
TW202100563A (zh) 2021-01-01
CN113767112A (zh) 2021-12-07
AU2020260931B2 (en) 2023-08-24
MX2021012964A (es) 2021-12-10
PE20220500A1 (es) 2022-04-07
AU2020260931A1 (en) 2021-12-09
KR20200124176A (ko) 2020-11-02
UA128626C2 (uk) 2024-09-04
JP2023115118A (ja) 2023-08-18
EP3978518A1 (en) 2022-04-06
KR102609627B1 (ko) 2023-12-04

Similar Documents

Publication Publication Date Title
JOP20210282A1 (ar) بولي ببتيد اندماج يتضمن منطقة fc لجلوبيولين مناعي وgdf15
WO2020014285A3 (en) Fusion constructs and methods of using thereof
PH12020551026A1 (en) Fusion protein comprising il-2 protein and cd80 protein, and use thereof
WO2016065326A3 (en) Modified fgf-21 polypeptides and uses thereof
AU2018351050A8 (en) Compositions and methods for selective protein degradation
EP3620474A4 (en) HUMAN FIBROBLAST GROWTH FACTOR 21 (HFGF21) FUSION PROTEIN, METHOD OF MANUFACTURING IT AND USES THEREOF
EP3735458A4 (en) RECOMBINANT HUMAN SIALIDASES, SIALIDASE FUSION PROTEINS AND METHODS OF USE THEREOF
EP3870211A4 (en) GLUCAGON-LIKE GROWTH DIFFERENTIATION FACTOR 15 (GDF15) PEPTIDE 1 (GLP1) FUSION PROTEINS AND USES THEREOF
CR20200510A (es) Protreínas de fusión del factor de diferenciación de crecimiento 15
UA41888C2 (uk) Злитий білок, який складається з мишачого або олюдненого моноклонального антитіла мав425 або його фрагменту, який спрямовано проти пухлинної клітини, спосіб його отримання, фармацевтична композиція
SG11202000115SA (en) Novel therapeutic enzyme fusion protein and use thereof
MX2022002747A (es) Proteinas de fusion de ca2-il15 para regulacion ajustable.
MY193353A (en) Anti-vegf protein compositions and methods for producing the same
EP3994275A4 (en) RECOMBINANT HUMAN SIALIDASES, SIALIDASE FUSION PROTEINS AND METHODS OF USE THEREOF
MX2023001595A (es) Proteinas de fusion que comprenden proteinas de leche y composiciones de las mismas.
MX2020006635A (es) Proteína de fusión enzimática terapéutica que tiene una nueva estructura y uso de la misma.
MX2022009100A (es) Proteinas de fusion fc heterodimericas il15/il15r alfa para el tratamiento de cancer.
WO2019108924A3 (en) Cdkl5 expression variants and cdkl5 fusion proteins
EP4063385A4 (en) GIPR ANTIBODY AND FUSION PROTEIN BETWEEN THE SAME AND GLP-1, AND PHARMACEUTICAL COMPOSITION AND ASSOCIATED APPLICATION
EP3853248A4 (en) FUSION PROTEINS FOR THE HYDROXYLATION OF AMINO ACIDS AND PRODUCTS
EP3848388A4 (en) FUSION POLYPEPTIDE INCLUDING A POLYPEPTIDIC REGION MAY BE O-GLYCOSYLATED
MX2022009101A (es) Proteinas heterodimericas con mutaciones fc.
DK0625157T3 (da) Blodplade-GPIIIaP1A1- og -P1A2-epitoper og fremstilling og anvendelse deraf
CR20220107A (es) Proteínas de fusión nkg2d y sus usos
EP3741774A4 (en) N-TERMINAL FUSION PARTNER FOR THE MANUFACTURING OF A RECOMBINANT POLYPEPTID AND PROCESS FOR THE MANUFACTURING OF A RECOMBINANT POLYPEPTID USING THESE